Once-daily roflumilast foam 0.3% for scalp and body psoriasis: a randomized, double-blind, vehicle-controlled phase IIb study
British Journal of Dermatology · 2023
DOI: 10.1093/bjd/ljad182 ↗Kurz gefasst
Randomisierte kontrollierte Studie in der Zeitschrift British Journal of Dermatology, 2023. Verfasst von Leon H Kircik und 20 weiteren Autor:innen. Beteiligte Einrichtung: Icahn School of Medicine at Mount Sinai, New York, NY, USA. Hauptthemen laut MEDLINE: Psoriasis, Dermatologic Agents. Die Arbeit wurde bisher 19-mal zitiert (Crossref) und nennt 27 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY 4.0).
Abstract (Originalsprache)
Background
Scalp psoriasis affects most patients with psoriasis, but it can be difficult to treat.
Objectives
To evaluate the efficacy and safety of once-daily roflumilast foam 0.3% on scalp and body psoriasis.
Methods
In a phase IIb randomized controlled trial, adults and adolescents aged ≥ 12 years with scalp and body psoriasis were randomized (2 : 1) to roflumilast foam 0.3% or vehicle for 8 weeks. The primary efficacy endpoint was scalp Investigator Global Assessment (S-IGA) success (score of ‘clear’ or ‘almost clear’ plus ≥ 2-grade improvement from baseline) at week 8. Safety and tolerability were also evaluated.
Results
Significantly more roflumilast-treated patients (59.1%) than vehicle-treated patients (11.4%) achieved S-IGA success at week 8 (P < 0.001); differences favoured roflumilast as early as the first postbaseline visit at week 2 (P < 0.001). Significant improvements were also seen for secondary endpoints, including body IGA success, Scalp Itch Numeric Rating Scale and the Psoriasis Scalp Severity Index. The safety of roflumilast was generally similar to vehicle. Patients treated with roflumilast experienced low rates of treatment-emergent adverse events (AEs), with few discontinuations due to an AE. Few patients with skin of colour (11%) and few adolescents (0.7%) were included.
Conclusions
The results support the further development of roflumilast foam for treating scalp and body psoriasis.
Schlagwörter
MeSH-Schlagwörter (MEDLINE)
Substanzen
Autor:innen und Institutionen
- Icahn School of Medicine at Mount Sinai, New York, NY, USA.
- Indiana Medical Center, Indianapolis, IN, USA.
- Physicians Skin Care PLLC, Louisville, KY, USA.
- Skin Sciences PLLC, Louisville, KY, USA.
- Driven Research LLC, Coral Gables, FL, USA.
- Therapeutics Clinical Research, San Diego, CA, USA.
ORCID-Profile: Dedee F Murrell, Kim A Papp
Zitieren
APA
Kircik, L. H., Alonso-Llamazares, J., Bhatia, N., Bukhalo, M., Devani, A. R., Draelos, Z. D., DuBois, J., Gooderham, M. J., Kempers, S. E., Lain, E., Lee, M., Moore, A., Murrell, D. F., Papp, K. A., Pariser, D. M., Sinclair, R., Zirwas, M., Burnett, P., Higham, R. C., …, & Berk, D. R. (2023). Once-daily roflumilast foam 0.3% for scalp and body psoriasis: a randomized, double-blind, vehicle-controlled phase IIb study. British Journal of Dermatology. https://doi.org/10.1093/bjd/ljad182
Vancouver
Kircik LH, Alonso-Llamazares J, Bhatia N, Bukhalo M, Devani AR, Draelos ZD, et al. Once-daily roflumilast foam 0.3% for scalp and body psoriasis: a randomized, double-blind, vehicle-controlled phase IIb study. British Journal of Dermatology. 2023. doi:10.1093/bjd/ljad182
BibTeX
@article{Kircik2023,
author = {Kircik, Leon H and Alonso-Llamazares, Javier and Bhatia, Neal and Bukhalo, Michael and Devani, Alim R and Draelos, Zoe D and DuBois, Janet and Gooderham, Melinda J and Kempers, Steven E and Lain, Edward and Lee, Mark and Moore, Angela and Murrell, Dedee F and Papp, Kim A and Pariser, David M and Sinclair, Rodney and Zirwas, Matthew and Burnett, Patrick and Higham, Robert C and Krupa, David and Berk, David R},
title = {Once-daily roflumilast foam 0.3% for scalp and body psoriasis: a randomized, double-blind, vehicle-controlled phase IIb study},
journal = {British Journal of Dermatology},
year = {2023},
doi = {10.1093/bjd/ljad182}
}
EUVIMED